US judge rejects German drug maker's effort to halt execution

Image
AFP Chicago
Last Updated : Aug 11 2018 | 6:00 AM IST

A US judge denied German drugmaker Fresenius Kabi's motion to stop a planned lethal injection execution in Nebraska on the grounds that the state improperly obtained the company's drugs.

Federal Judge Richard Kopf ruled yesterday that the state could carry out the execution, its first in 21 years, using a four-drug protocol.

Fresenius Kabi had argued it was the likely source of two of those drugs, and their use in an execution would hurt the company's reputation, especially with a European public largely opposed to capital punishment.

The German group argued that it had protocols in place to prevent its drugs from being obtained by state agencies for executions, and that if Nebraska had purchased the drugmaker's injectable medicines, it had done so improperly.

But Kopf rejected the company's arguments, issuing an oral ruling from the bench saying that since Nebraska has not publicly identified the source of its execution drugs, the company's concerns were too speculative.

Fresenius Kabi reportedly planned to appeal the ruling, which for the time being did not alter the planned execution date of convicted murderer Carey Dean Moore, set for Tuesday.

Moore was sentenced to death for the 1979 murder of two taxi drivers. He is not contesting his execution order, but it could nevertheless be delayed by the lawsuit, should it prevail in an appeal.

"Decades have slipped by since Mr Moore was sentenced to death. The people of Nebraska have spoken," the judge said in his ruling.

"Any delay now is tantamount to nullifying Nebraska law, particularly given the rapidly approaching expiration of two of the drugs and the total absence of any feasible alternatives." State officials have said they obtained the drugs legally, although they have kept their source secret.

Injectable drugs have become harder to obtain amid public opposition and a reluctance or refusal by drug manufacturers to sell their products to prisons for use in executions.

Last month, a similar lawsuit by drugmaker Alvogen temporarily halted an execution in Nevada.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 11 2018 | 6:00 AM IST

Next Story